The new consensus, published in the World Journal of Pediatrics, was developed following the World Health Organization’s Handbook for Guideline Development, a rigorous process that included systematic reviews of the literature and structured expert discussion. The panel formulated 20 clinical questions and ultimately issued 33 recommendations covering the full arc of care: diagnostic steps, anticoagulant therapy, thrombolysis, catheter-based interventional procedures, surgical embolectomy, the role of multidisciplinary teams, management of children with comorbidities, prognosis, education, and follow-up. Strikingly, the evidence base underpinning these recommendations was thin. Eighteen of the recommendations are weak recommendations resting on very low quality evidence, and fifteen are so-called good practice statements, reflecting consensus expert judgment in the absence of robust trial data.

The rarity of pediatric pulmonary thromboembolism is precisely why such guidance has been so slow to materialize. Randomized controlled trials in children are exceedingly difficult to conduct for any condition, let alone one that is uncommon enough that even large pediatric centers may see only a handful of cases per year. Adults with pulmonary embolism benefit from well-established clinical guidelines built on extensive trial data, but children differ from adults in crucial ways: their clotting systems are still maturing, the causes of their clots are different, their symptoms present differently, and the safety and dosing of anticoagulant and thrombolytic drugs in growing bodies cannot simply be extrapolated downward from adult protocols.

One of the consensus’s central messages concerns the treacherous nonspecificity of symptoms. The panel’s own meta-analysis, drawing on multiple studies, found that the most common clinical manifestations of pulmonary thromboembolism in children are dyspnea, cough, chest pain, shortness of breath, and hemoptysis, findings that apply even to children too young to verbalize their distress. The classic adult triad of hemoptysis, chest pain, and dyspnea, so often cited in medical teaching, appears far less reliably in pediatric patients, and small sample sizes in the underlying studies further weaken confidence in those classic presentations. In practice, this means a child presenting with what looks like a routine respiratory infection, an asthma exacerbation, or even unexplained fussiness could in fact be harboring a pulmonary embolus, and clinicians must maintain a high index of suspicion, particularly in children with known risk factors.

Risk stratification is where the consensus begins its diagnostic algorithm. For children with suspected pulmonary thromboembolism, the panel recommends assessment based on clinical experience and, where available, validated clinical likelihood rating scales. Children judged to have a high probability on clinical evaluation may proceed directly to definitive diagnostic imaging. For those with low clinical probability, the panel recommends measurement of D-dimer, a protein fragment released when a blood clot breaks down. If the D-dimer level falls below the thrombotic threshold, pulmonary thromboembolism is considered sufficiently unlikely that no further testing may be needed, sparing the child unnecessary radiation and contrast exposure. If the level is elevated, imaging follows. This tiered approach mirrors adult practice but is calibrated to pediatric considerations, since children have lower baseline D-dimer values that rise predictably with age, a physiological nuance that must be accounted for when interpreting results.

For definitive diagnosis, computed tomographic pulmonary angiography remains the cornerstone, offering rapid, detailed visualization of the pulmonary arteries. The consensus also addresses the role of echocardiography, which can reveal indirect signs of pulmonary arterial obstruction such as right ventricular strain and tricuspid systolic murmur, findings the panel highlighted in good practice statements. Electrocardiographic and radiographic findings, while nonspecific, contribute to the overall clinical picture. The panel emphasizes that no single test should be interpreted in isolation; diagnosis in children is fundamentally probabilistic, weaving together history, physical examination, laboratory markers, and imaging.

Once diagnosis is confirmed or sufficiently suspected, treatment decisions hinge on the severity of presentation and the stability of the patient. The consensus lays out a graduated therapeutic ladder. Anticoagulant therapy forms the foundation of treatment for most children, preventing clot propagation and allowing the body’s own fibrinolytic systems to dissolve the existing thrombus over time. For children with massive pulmonary embolism and hemodynamic compromise, more aggressive options come into play: systemic thrombolysis, in which clot-dissolving drugs are infused to break down the obstruction rapidly; catheter-based interventional therapy, in which devices are threaded through the vasculature to mechanically remove or fragment the clot; and, in the most extreme cases, surgical embolectomy. Each option carries its own risk profile in children, from bleeding complications with thrombolytics to the technical demands of pediatric interventional procedures, and the panel’s recommendations weigh effectiveness against resource availability, feasibility, and the values and preferences of families, in keeping with the GRADE Evidence to Decision framework used throughout the document.

The GRADE approach, short for Grading of Recommendations Assessment, Development, and Evaluation, deserves particular attention because it shapes how the entire consensus should be read. Under GRADE, evidence from randomized trials ranks high, while observational studies, case series, and expert opinion rank progressively lower. For pediatric pulmonary thromboembolism, nearly the entire literature consists of small observational studies and case reports, which is why the panel issued so many weak recommendations based on very low quality evidence. A weak recommendation signals that informed clinicians and families may reasonably make different choices depending on circumstances, in contrast to strong recommendations that most patients should receive. The fifteen good practice statements cover actions the panel judged self-evidently beneficial, such as specific physical examination maneuvers, that do not lend themselves to formal evidence grading.

Beyond acute management, the consensus takes a notably holistic view of care. It addresses the management of children with comorbidities, recognizing that pediatric pulmonary thromboembolism frequently arises in the context of underlying conditions such as congenital heart disease, central venous catheters, infections, malignancy, or inherited thrombophilias, each of which alters both treatment strategy and recurrence risk. It also emphasizes the importance of a multidisciplinary team, bringing together pediatric hematologists, cardiologists, intensivists, radiologists, and surgeons to navigate complex cases. Patient and family education, psychological support, structured follow-up to monitor for long-term sequelae such as chronic thromboembolic pulmonary hypertension, and careful planning around the duration of anticoagulation all receive explicit attention, areas that adult guidelines often treat as afterthoughts but that are especially consequential for children who must live for decades after the event.

The publication of this consensus is likely to resonate far beyond the specialist community that produced it. Pediatric pulmonary embolism appears to be diagnosed with increasing frequency, a trend attributed by many observers to greater clinical awareness, expanded use of sensitive imaging, and a growing population of children surviving complex illnesses that predispose them to thrombosis, including premature infants with central lines and children undergoing treatment for cancer. As more clinicians encounter these cases, having a shared, transparent framework for decision-making reduces unwarranted variation in care, which in a rare disease can otherwise be enormous, with some centers following adult protocols and others relying entirely on local convention.

The panel is candid about the limitations of what it has produced and explicit about what must come next. In its conclusions, it calls for urgent research into early identification and diagnostic strategies tailored to children, into preventive and therapeutic regimens tested in pediatric populations rather than extrapolated from adults, and into long-term management and outcomes. Until such research exists, the consensus stands as both a practical tool and a benchmark: a document that codifies the best of current knowledge while mapping, question by question, exactly where the evidence runs out. For the children whose lives depend on rapid recognition of a clot in the lungs, and for the clinicians confronting those moments without precedent to guide them, that map may prove as valuable as the recommendations themselves.